Bibby Scientific purchased 100% of the share capital of U.K.-based PCR and qPCR-focused sales and distribution firm PCRmax. PCRmax is a registered owner of IP previously owned by Illumina with respect to the Eco™ qPCR instrument.

PCRmax is launching the Eco 48-well qPCR platform along with a range of qPCR research kits and consumables. The firm says the platform can allow researchers to complete a real-time experiment in eight minutes. It also plans to launch three more instruments in the PCR and qPCR range plus supporting life science products over the following 12 months. 

Bibby CEO James Heffernan, Ph.D., said in a statement that this acquisition underscores the firm's goal to become a global player in the life science equipment market. “The addition of a comprehensive range of quality research kits for use on the new platforms should prove a compelling offering to our customers,” he added.

Previous articleAcorda Buys Civitas and Its Phase III PD Candidate for $525M
Next articleGenzyme to Provide $900K Grant to UF Researcher Focused on Rare Eye Disease